BIB is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of the Nasdaq Biotechnology Index (NBI), a modified market-capitalization-weighted benchmark of biotechnology and pharmaceutical companies listed on the Nasdaq. Because the fund resets its leverage daily, its returns over periods longer than a single day can diverge materially from a simple multiple of the index's cumulative return, a phenomenon often described as compounding or volatility drag.
The fund holds roughly 250 equity positions while also using total-return swaps on the Nasdaq Biotechnology Index to achieve its leveraged exposure. Its portfolio is almost entirely concentrated in the health care sector, and its largest equity holdings include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). The fund is non-diversified, carries a net expense ratio of 0.95%, and manages roughly $90–100 million in assets under management (AUM). This concentrated, leveraged structure means BIB tends to amplify the sector's price swings, which helps explain both its sharp rallies and its pronounced drawdowns.
Over the last 30 days, BIB declined approximately 11%, moving from a level near $57 to roughly $51. The move was not a smooth decline: the fund climbed to a local peak near $60 in late October before reversing sharply and giving back those gains over the following three weeks, a pattern consistent with a volatile, momentum-driven reversal rather than a gradual drift lower.
The trailing three-month picture is similarly weak. Over the trailing quarter, BIB fell about 14%, from near $59 to roughly $51. That period also included a meaningful late-summer rally that took the fund above $63 in August before a series of selloffs erased the advance. In both windows, the leveraged structure converted moderate moves in the underlying Nasdaq Biotechnology Index into larger percentage swings in the fund.
The recent decline largely reflected a broad pullback across large-cap biotechnology and pharmaceutical stocks, which dominate the Nasdaq Biotechnology Index and, in turn, BIB's exposure. Because holdings such as Amgen, Gilead Sciences, Vertex, and Regeneron carry outsized index weight, weakness in these names has a disproportionate effect on the fund, and BIB's 2x leverage doubles the impact on a daily basis.
The sector's sensitivity to the interest-rate backdrop was also a central factor. Biotechnology companies are widely treated as long-duration growth assets, because their valuations depend heavily on discounted future cash flows from products that may be years from commercialization. When bond yields rise or risk appetite cools, these stocks often underperform, and leveraged vehicles such as BIB feel the pressure more acutely. A rotation away from higher-beta growth and into more defensive or rate-resilient segments contributed to the downdraft, while the absence of a broad sector-wide catalyst left the group vulnerable to profit-taking after its late-October advance.
Over the trailing quarter, BIB's roughly 14% decline reflected a broader pattern of biotechnology underperformance amid shifting macro conditions. The fund's August strength gave way to repeated bouts of selling as investors reassessed valuations across the growth-oriented health care complex. Sector rotation away from higher-multiple names, combined with the mechanical effects of daily leverage resetting, weighed on the fund over the multi-month horizon.
The concentration of the underlying index in a handful of mega-cap constituents also mattered. When sentiment toward those largest holdings soured, the entire fund followed, and the leveraged structure amplified the result. Meanwhile, mid- and small-cap biotech names, which are sensitive to funding conditions and clinical news flow, added to the volatility even though they represent smaller individual weights. Institutional flows in and out of leveraged biotech products can further exaggerate short-term moves in a fund of BIB's size.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. Instead of manually reviewing hundreds of charts, users can apply customizable criteria to surface securities that match specific technical or fundamental conditions across sectors and industries. The screener is designed to make the research process more efficient and objective, helping traders and investors identify trending names, momentum shifts, and emerging opportunities with less manual effort. Explore the screener to refine your ETF analysis and uncover signals aligned with your investment themes.
Looking ahead, the most important factors for BIB are likely to be the direction of interest rates and inflation, which heavily influence how investors value long-duration biotechnology assets. A more restrictive rate environment tends to pressure the sector, while declining yields and improving risk appetite historically support biotech valuations.
Investors should also monitor earnings and pipeline updates from the fund's largest holdings, including Amgen, Gilead, Vertex, Regeneron, and Alnylam, as well as clinical-trial readouts, Food and Drug Administration decisions, and merger-and-acquisition activity across the sector. Sector rotation, institutional fund flows, and the pace of innovation in areas such as oncology, immunology, and genetic medicines will shape the index's trajectory. Because BIB resets its leverage daily, volatility itself is a key risk: choppy, range-bound markets can erode returns through compounding even when the underlying index is flat. These structural dynamics, rather than any single headline, are likely to remain the dominant influence on the fund over the coming months.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BIB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 45 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIB as a result. In 78 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
BIB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for BIB crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +10.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIB advanced for three days, in 292 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 200 of 219 cases where BIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows